No Data
Is TScan Therapeutics (NASDAQ:TCRX) A Risky Investment?
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics Analyst Ratings
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $11
TScan Therapeutics Announces Upcoming Oral Presentation of Data From the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
Express News | TScan Therapeutics Announces Upcoming Oral Presentation of Data From the Alloha™ Phase 1 Heme Trial at the 66TH American Society of Hematology Annual Meeting and Exposition
No Data
No Data